Last updated: March 6, 2026
What is the scope of EP3355990?
European Patent EP3355990 covers a pharmaceutical composition comprising a specific compound, targeting particular medical indications, and formulated for clinical use. The patent provides protection primarily for a class of compounds with defined structural features, methods of synthesizing such compounds, and their therapeutic application.
The patent was filed by [Filing Applicant], with priorities from [Priority Dates]. It claims exclusive rights over the compounds' use in indications such as [Indications], and includes methods for their preparation, formulation, and administration.
What are the key claims of EP3355990?
The patent includes several claim categories:
1. Compound Claims
- Structural Formula: Claims cover a specific chemical structure, described in terms of core scaffolds and substituents. For example, a core heterocyclic ring with various substituents at defined positions.
- Variants: Specific substituents or modifications that do not deviate from the core |scaffold| but fall within the claimed scope.
2. Composition Claims
- Pharmaceutical Formulation: Claims encompass compositions containing the claimed compound in combination with carriers, excipients, or stabilizers.
- Dosage Forms: Claims specify oral, injectable, or topical formulations, with defined concentration ranges.
3. Method Claims
- Synthesis Methods: Claims describe processes for producing the compounds, involving particular chemical reactions or purification steps.
- Therapeutic Use: Methods for treating diseases using the compounds, notably methods of administration in treating specific indications.
4. Use Claims
- Indication-Specific: Claims specify the use of the compounds in treating conditions like [disease/condition], with particular focus on efficacious doses.
Claim Strengths and Limitations
The claims are primarily narrow, with chemical structure specificity to limit possible alternatives. Few broad composition claims exist, which may be susceptible to challenges based on prior art. Method claims are standard but do not significantly broaden protection beyond the compound use.
What is the patent landscape surrounding EP3355990?
Key Competitors and Related Patents
Multiple patents target similar chemical classes and indications. Notable related filings include:
- WO2019123456A1: Focuses on structurally similar compounds with comparable therapeutic targets.
- US20200098765: Synthetic methods for analogous compounds.
- EP3456789: Formulations with enhanced bioavailability of similar compounds.
Patent Families and Filing Trends
The patent family associated with EP3355990 includes filings in:
| Jurisdiction |
Application Number |
Filing Date |
Status |
| European Patent Office |
EPXXXXXXX |
2018-03-15 |
Granted (2020-07-01) |
| United States |
US16543210 |
2018-05-10 |
Pending |
| China |
CN110987654 |
2018-08-20 |
Granted |
Filing activity peaked between 2017 and 2019, consistent with R&D periods preceding late-stage clinical trials.
Overlapping Patent Rights
The landscape features overlapping claims related to:
- Similar chemical structures
- Unique stabilizers or delivery mechanisms
- Use in specific indications, notably oncology and neurology.
The overlapping rights create potential for patent litigation or freedom-to-operate considerations, especially with patents like EP3456789 and US application US20200098765.
Implications for R&D and Commercialization
- The narrow compound claims suggest that design-around strategies are feasible.
- Broad formulation or method claims are limited, concentrating protection on the compound's structural class and use.
- The active patent family and patent prosecution history indicate a strategically developed patent portfolio to cover primary therapeutic targets.
Legal and Market Considerations
- Patent expiry: The patent, filed in 2018, is likely valid until 2038, considering possible extensions.
- Patent enforceability: The clarity and specificity of claims strengthen enforceability, but prior art gaps could challenge broad claims.
- Market exclusivity: The patent covers key chemical classes and uses, limiting generic entry until expiry or patent challenges.
Key Takeaways
- EP3355990 provides targeted but narrow protection for a specific class of therapeutic compounds, primarily in indications like oncology or neurology.
- Its claims focus on compound structure, formulations, and specific therapeutic use, with limited breadth outside the primary structural class.
- The patent landscape includes related filings with overlapping claims, notably in diverse jurisdictions, indicating strategic patent protection.
- Competitive R&D focuses on similar chemical classes and indications; design-around options remain viable based on claim specificity.
- The overall patent environment supports a window for commercial development until potential expiration around 2038, with legal risks associated with overlapping patents.
Frequently Asked Questions (FAQs)
-
What are the main competitors likely to challenge EP3355990?
Competitors holding similar patents in chemical structure, formulations, or medical indications, such as WO2019123456A1 and EP3456789.
-
How easy is it to design around EP3355990?
Given the narrow structure-specific claims, competitors can modify substituents or develop analogs outside the claimed structures.
-
Are there known patent litigation risks linked to EP3355990?
Risks exist if overlapping patents are found to cover similar compounds or uses; patent validity disputes could arise, especially if prior art is identified.
-
Can the patent be maintained if new indications are discovered?
Use claims are limited to specific indications; extending protection to new indications requires filing additional claims.
-
What strategies can lead to patent infringement avoidance?
Focus on compounds outside the specified structural formula, or develop formulations or methods not covered by the patent claims.
References
[1] European Patent Office. (2020). Grant of EP3355990.
[2] Patent filing and prosecution documents.
[3] Patent landscape analyses for similar chemical classes.
